<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343525</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 0601</org_study_id>
    <nct_id>NCT00343525</nct_id>
  </id_info>
  <brief_title>Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C</brief_title>
  <official_title>A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of bavituximab when&#xD;
      administered via an arm vein as multiple infusions and to examine how bavituximab behaves in&#xD;
      the body and how it effects the amount of hepatitis C virus and immune modulators in&#xD;
      individuals with chronic infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is a world wide public health concern and is the most&#xD;
      common chronic bloodborne infection in the United States and the leading indication for liver&#xD;
      transplantation. Laboratory and animal studies have demonstrated that bavituximab binds&#xD;
      viruses and virally infected cells and prolongs survival in lethally infected animals. This&#xD;
      study will examine the safety and tolerability of bavituximab when administered as multiple&#xD;
      infusions to patients with chronic HCV infection. Groups of patients will be treated with&#xD;
      escalating doses of bavituximab twice weekly for 2 weeks and followed for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory evaluations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>human anti-chimeric antibody</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic analysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>viral kinetic analysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>cytokine analysis</measure>
  </primary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bavituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Chronic Hepatitis C infection based on history and detectable serum HCV RNA including&#xD;
             treatment na√Øve subjects as well as subjects who are partial responders and/or&#xD;
             relapsers to prior therapy(ies)&#xD;
&#xD;
          -  All genotypes of HCV acceptable&#xD;
&#xD;
          -  Complete Blood Counts within normal limits&#xD;
&#xD;
          -  Normal renal function (serum creatinine within normal limits)&#xD;
&#xD;
          -  Normal coagulation profile (PT/INR and aPTT within normal limits)&#xD;
&#xD;
          -  Patients of reproductive potential must agree to use an approved form of barrier&#xD;
             contraception. Female patients must have a negative serum pregnancy test at prestudy&#xD;
             (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to&#xD;
             those patients who are postmenopausal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to any chimeric antibody&#xD;
&#xD;
          -  Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or&#xD;
             alcoholic liver disease.&#xD;
&#xD;
          -  Decompensated clinical liver disease, including a history of prolonged clotting times,&#xD;
             hypoalbuminemia, encephalopathy, treatment for elevated ammonia levels, or ascites&#xD;
&#xD;
          -  Any evidence of clinically significant bleeding defined as gross hematuria,&#xD;
             hemoptysis, or gastrointestinal bleeding&#xD;
&#xD;
          -  Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease or&#xD;
             Hemophilia)&#xD;
&#xD;
          -  Any history of thromboembolic events [e.g., deep vein thrombosis (DVT) or pulmonary&#xD;
             thromboembolism (PE)] including central venous catheter-related thrombosis within the&#xD;
             past 12 months&#xD;
&#xD;
          -  Concurrent therapy with oral or parenteral anticoagulants&#xD;
&#xD;
          -  Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement,&#xD;
             anti-estrogen)&#xD;
&#xD;
          -  Antiviral therapy within 4 weeks of day 0&#xD;
&#xD;
          -  Investigational therapy within 4 weeks of day 0&#xD;
&#xD;
          -  Major surgery within 4 weeks of day 0&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)&#xD;
&#xD;
          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,&#xD;
             or transient ischemic attack&#xD;
&#xD;
          -  A history of any condition requiring anti-platelet therapy with the exception of&#xD;
             general cardiovascular prophylaxis with aspirin&#xD;
&#xD;
          -  A history of any condition requiring treatment (past or current) with coumarin-type&#xD;
             agents&#xD;
&#xD;
          -  Cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
          -  Serious non-healing wound (including wound healing by secondary intention, ulcer, or&#xD;
             bone fracture)&#xD;
&#xD;
          -  Requirement for chronic daily treatment with NSAIDs, antiplatelet drugs (e.g.,&#xD;
             phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids&#xD;
&#xD;
          -  Cancer, autoimmune disease or any disease or concurrent therapy known to cause&#xD;
             significant alteration in immunologic function&#xD;
&#xD;
          -  Known chronic infection with HIV or HBV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lawitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alamo Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eliot W Godofsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hepatitis Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hepatitis Center at Bach &amp; Godofsky MD PA</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>June 21, 2006</study_first_submitted>
  <study_first_submitted_qc>June 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>April 28, 2008</last_update_submitted>
  <last_update_submitted_qc>April 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dianne Uphoff/Senior Clinical Project Manager</name_title>
    <organization>Peregrine Pharmaceuticals</organization>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

